Across TCGA pan-cancer cohorts, C9orf163 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C9orf163 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher C9orf163 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C9orf163 expression acts as an unfavorable survival marker.

LIHC and UCEC are the cancer types where C9orf163 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.116	0.544	.007	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: C9orf163 tumor-vs-normal RNA expression · all C9orf163 data types